AbbVie (ABBV)
(Delayed Data from NYSE)
$193.47 USD
-0.15 (-0.08%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $193.31 -0.16 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$193.47 USD
-0.15 (-0.08%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $193.31 -0.16 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
AbbVie (ABBV) closed at $193.45 in the latest trading session, marking a -1.16% move from the prior day.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
TEVA Stock Rises 72.5% This Year: Time to Buy, Sell or Hold?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline and the prospect of growth in sales and profits are good enough reasons for those who own the stock to stay invested.
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
FDA Grants Label Expansion to J&J's Tremfya in Ulcerative Colitis
by Zacks Equity Research
With this latest approval, JNJ's Tremfya is approved for a total of three immunology indications.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian
by Zacks Equity Research
Visa, AbbVie, Anheuser-Busch, Servotronics and United-Guardian are included in this Analyst Blog.
Top Stock Reports for Visa, AbbVie & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Why AbbVie (ABBV) Outpaced the Stock Market Today
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) concluded the recent trading session at $197.69, signifying a +0.7% move from its prior day's close.
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
by Zacks Equity Research
Though data from a mid-stage study shows that treatment with NBIX's schizophrenia drug is effective, results lag behind drugs being developed by its peers.
Why Is Pfizer (PFE) Down 5.9% Since Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWV
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
by Kinjel Shah
LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
by Zacks Equity Research
AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for HDV
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
by Zacks Equity Research
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.